Inpefa Generic: When Will Generic Sotagliflozin Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Inpefa Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? May 2033 About 6.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? October 2030 3 patents listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
Generic sotagliflozin is expected to be available in May 2033, about 6.5 years away. None is for sale yet.
Why May 2033?
It is when Inpefa’s patent 7,781,577 ends. That patent covers the active ingredient, the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Inpefa as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Inpefa by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $9M a yearSmaller seller
- FDA approved 2023 May 2023 FDA Orange Book
- Patents listed 3 last runs to October 2030 FDA Orange Book
- Pharmacies pay $20.37 per tablet NADAC, October 2026
- Medicare Part D spent $6.7M in 2025, for 1,541 people CMS Part D Spending by Drug
- Medicaid prescriptions 660 in the last four reported quarters, $518.9K CMS Medicaid drug utilization, to Q1 2026
Inpefa’s Road to a Generic
Inpefa has had the market to itself since the FDA approved it in May 2023 (Lexicon Pharmaceuticals Inc). Its FDA protection (new chemical entity) runs to May 2028. Its 3 listed patents run to October 2030.
The first generic of Inpefa is expected in May 2033.
Why that month: patent 7,781,577, on the active ingredient, the product’s formulation and a way of using it, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Inpefa Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Inpefa’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 7,781,577, which ends in May 2028; the first generic is expected after it, in May 2033, about 6.5 years away.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 7,781,577 Sets the expected month of generic availability | The active ingredient; the product’s formulation; a way of using it (U-3628) | May 2028 | Active |
| 8,476,413 | The active ingredient; the product’s formulation; a way of using it (U-3628) | May 2028 | Active |
| 8,217,156 | The active ingredient; the product’s formulation | October 2030 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New chemical entity NCE | Five years of protection for a medicine whose active ingredient the FDA had never approved before. | May 2028 | Active |
Source: FDA Orange Book, application 216203. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Sotagliflozin
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Inpefa yet.
Approved by the FDA
Not yet. The FDA has not approved a generic sotagliflozin. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic sotagliflozin for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Inpefa Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Inpefa 200 mg tablet
$20.37 per tablet in October 2026.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $20.37 |
| September 2026 | $20.37 |
| August 2026 | $20.46 |
| July 2026 | $20.50 |
| June 2026 | $20.50 |
| May 2026 | $20.34 |
| April 2026 | $20.34 |
| March 2026 | $20.34 |
| February 2026 | $20.34 |
| January 2026 | $20.34 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Inpefa today: $20.37 per tablet for Inpefa 200 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Dollar figures apply FDA’s median drops to the $20.37 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Inpefa
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Inpefa, before manufacturer rebates.
- $1.2M
- January to March 2026, the latest CMS has posted
For 791 people, about $826 per prescription fill - $6.7M
- 2025, the whole year
For 1,541 people, about $791 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $1,197,676 | 791 | $825.98 |
| 2025 | $6,674,038 | 1,541 | $790.67 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Inpefa only, so no generic is counted in it. What CMS says it is used for: Sotagliflozin is used by people with heart failure or by people with type 2 diabetes, kidney disease, and other heart disease risk factors to lower the risk of death from heart disease and to reduce the need to go to a doctor or hospital to treat heart failure.
Medicaid Prescriptions by Quarter
660 prescriptions in the four quarters to Q1 2026, $518.9K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 94 | $76,770 |
| Q4 2025 | 145 | $114,124 |
| Q3 2025 | 219 | $172,254 |
| Q2 2025 | 202 | $155,723 |
| Q1 2025 | 265 | $200,146 |
Source: CMS Medicaid State Drug Utilization Data, over Inpefa’s own package codes.
Inpefa Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 200MG | Tablet | Oral | May 2023 | Prescription reference product |
| 400MG | Tablet | Oral | May 2023 | Prescription reference product |
Source: FDA Orange Book, Lexicon Pharmaceuticals Inc. Listed for sale today by Lexicon Pharmaceuticals, Inc. (FDA NDC Directory).
Inpefa NDC Codes and Packages
Each Inpefa package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 70183-0220-07 | SOTAGLIFLOZIN 200 mg/1 tablet | blister pack of 7 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0220-07 | SOTAGLIFLOZIN 200 mg/1 tablet | blister pack of 7 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0220-30 | SOTAGLIFLOZIN 200 mg/1 tablet | bottle of 30 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0220-30 | SOTAGLIFLOZIN 200 mg/1 tablet | bottle of 30 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0221-07 | SOTAGLIFLOZIN 200 mg/1 tablet | blister pack of 7 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0221-07 | SOTAGLIFLOZIN 200 mg/1 tablet | blister pack of 7 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0221-30 | SOTAGLIFLOZIN 200 mg/1 tablet | bottle of 30 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0221-31 | SOTAGLIFLOZIN 200 mg/1 tablet | blister pack of 3 blister packs of 10 tablets | Lexicon Pharmaceuticals, Inc. |
Show the other 3 Inpefa packages
| NDC | Product | Package | Company |
|---|---|---|---|
| 70183-0221-31 | SOTAGLIFLOZIN 200 mg/1 tablet | blister pack of 3 blister packs of 10 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0241-30 | SOTAGLIFLOZIN 400 mg/1 tablet | bottle of 30 tablets | Lexicon Pharmaceuticals, Inc. |
| 70183-0241-30 | SOTAGLIFLOZIN 400 mg/1 tablet | bottle of 30 tablets | Lexicon Pharmaceuticals, Inc. |
Source: the FDA NDC Directory, current listings only. Only packages sold under Inpefa’s own FDA approval (NDA 216203) are listed, never a generic. Some codes belong to companies that repackage Inpefa: it is the same medicine in a different package.
What a Generic Inpefa Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Inpefa as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Inpefa”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Inpefa
Is there a generic for Inpefa right now?
No. As of October 9, 2026 no generic sotagliflozin is listed for sale in the FDA NDC Directory.
When will Inpefa go generic?
May 2033 is the expected month, and that is probable but not certain. It is when Inpefa’s patent 7,781,577 ends. That patent covers the active ingredient, the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them.
Will generic sotagliflozin be the same as Inpefa?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Inpefa?
Not yet. The FDA Orange Book lists no approved generic version of Inpefa.
When does the Inpefa patent expire?
The FDA Orange Book lists 3 patents for Inpefa; the last runs to October 2030. The one behind the expected month is patent 7,781,577, which ends in May 2028. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (May 2033) weighs all of that.
How much does Inpefa cost now?
Pharmacies paid about $20.37 per tablet for Inpefa 200 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected May 2033 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- ThyquidityLevothyroxine Sodium2027 to 2028
- LinzessLinaclotideMarch 2029
- FinteplaFenfluramine HydrochlorideOctober to December 2033
- BrexafemmeIbrexafungerp Citrate2037 to 2039
- YeztugoLenacapavir Sodium2041 to 2042
- PluvictoLutetium Lu 177 Vipivotide TetraxetanSeptember 2041
About Inpefa
- Generic name sotagliflozin
- How it is taken By mouth
- Company Lexicon Pharmaceuticals Inc
- More drugs Brand-name drugs starting with I
- Have a question? A pharmacist answers, free. Ask about Inpefa
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.